SecBot SecBot

CELUW

Celularity Inc
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001752828 Biotech & Drug Discovery
Former ticker of Celularity Inc · CELU stock page →
—
Market cap
$55.0K
Nano cap
1 year
−64.1%
from $2.09 · Oct 27
30 days
−46.4%
from $1.40
52-week range
$0.5980–2.10
−64% from high · low Jun 30
Avg volume 20D
138.1K
Oct 26 spike 628.7K
Short interest
106.4K
≈0.4% of shares · +89.3%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read BEARISH 3 reports · latest
Balance 2 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest BEARISH Celularity Inc. entered into a Settlement Agreement with Helena Global Investment Opportunities 1 Ltd to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • Short sellersBUILDING

    Short interest +89.3% to 106.4K shares. 1.0 days to cover, ≈0.4% of shares.

  • TrendDOWNTREND

    43% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM14,619$66.00
UBS Group AGDOUBLED5,278$21.00
UBS Group AGADD1,913$31.00

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 22, 2026
Press release
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
Celularity regains Nasdaq reporting compliance and begins a finance department overhaul to strengthen accountability and ensure timely financial...
Sep 30, 2026
Contract
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative…
Sep 24, 2026
Earnings
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
Celularity closes $10 million financing in an up to $28 million recapitalization, advancing growth and targeting positive operating cash flow by Q1…
Aug 25, 2026
Earnings
Celularity Provides Update Regarding Nasdaq Listing Compliance
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it…
Jul 23, 2026
Listing
Delisted: CELUW — removed from the Nasdaq symbol directory
Celularity Inc. - Warrant

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Jul 15, 2026
106,447
shares short
+89.3%
vs prior settlement
1.0
days to cover
≈0.4%
of shares outstanding
Trading halts
Jul 20, 2026DeletionResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Other
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
Celularity regains Nasdaq reporting compliance and begins a finance department overhaul to strengthe
Jun 30, 2026 Inst.
SUSQUEHANNA INTERNATIONAL GROUP, LLP — TRIM
14,619 shares ($66.00)
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
5,278 shares ($21.00)
Jun 3, 2026 SEC
Celularity appointed Rick Gonzalez as Chief Commercial Officer (effective May 29, 2026) and issued a shareholder…
8-K — Impact 3/10
May 28, 2026 SEC
Celularity Inc. entered into a Settlement Agreement with Helena Global Investment Opportunities 1 Ltd to resolve…
8-K — Impact 6/10
Apr 21, 2026 SEC
Celularity announced the closing of its asset sale and licensing deal with NexGel, receiving $13.3 million in cash and…
8-K — Impact 8/10

SecBot reports

3 filings · 0 bullish · 2 bearish · 1 neutral
All CELUW filing & press-release reports (3)